33 patents
Utility
Chimeric Cytokine Receptors Bearing a PD-1 Ectodomain
18 Jan 24
Provided herein are PD-1 chimeric cytokine receptors.
Regina Junhui LIN, Thomas John VAN BLARCOM, Siler PANOWSKI, Barbra Johnson SASU
Filed: 3 Aug 23
Utility
Anti-talen Antibodies and Uses Thereof
4 Jan 24
The present disclosure provides, among other things, antibodies for detecting TALENs and/or FokI nucleases in a sample and methods of using the same.
Thomas Charles PERTEL, Barbra Johnson SASU
Filed: 18 Jul 23
Utility
Methods for Donor Cell Analysis
21 Dec 23
Provided herein are methods, kits and reagents for analyzing the attributes of cell populations, such as donor cells prior to modification to provide engineered cells, e.g., engineered immune cells, such as CAR T cells.
Meng-Yin LIN, Hayung YOON, Thomas Charles PERTEL, Barbra Johnson SASU
Filed: 28 Apr 23
Utility
Chimeric Switch Receptors for the Conversion of Immunesuppressive Signals to Costimulatory Signals
2 Nov 23
Provided herein are chimeric switch receptors (CSRs) comprising an ectodomain and/or transmembrane domain derived from an inhibitory receptor (e.g.
Yi ZHANG, Silvia K. TACHEVA-GRIGOROVA, Barbra Johnson SASU, Siler PANOWSKI, Regina Junhui LIN, Zhe LI
Filed: 29 Mar 23
Utility
Chimeric cytokine receptors bearing a PD-1 ectodomain
17 Oct 23
Provided herein are PD-1 chimeric cytokine receptors.
Regina Junhui Lin, Thomas John Van Blarcom, Siler Panowski, Barbra Johnson Sasu
Filed: 28 Feb 20
Utility
Anti-TALEN antibodies and uses thereof
10 Oct 23
The present disclosure provides, among other things, antibodies for detecting TALENs and/or FokI nucleases in a sample and methods of using the same.
Thomas Charles Pertel, Barbra Johnson Sasu
Filed: 12 Jun 20
Utility
DLL3 Targeting Chimeric Antigen Receptors and Binding Agents
14 Sep 23
Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells.
Yi ZHANG, Thomas John VAN BLARCOM, Siler PANOWSKI, Silvia K. TACHEVA-GRIGOROVA, Barbra Johnson SASU
Filed: 27 Apr 23
Utility
Antibodies against 4G7-derived chimeric antigen receptors
22 Aug 23
Provided herein are isolated antibodies that specifically bind anti-CD19 chimeric antigen receptors (CARs) derived from a 4G7 scFv.
Thomas Charles Pertel, Barbra Johnson Sasu, Tao Sai
Filed: 17 Apr 20
Utility
Combination Therapies of Chimeric Antigen Receptors Targeting B-cell Maturation Antigen and Gamma Secretase Inhibitors
13 Apr 23
Provided herein are BCMA CARs and CAR-T cells, gamma secretase inhibitors, and the combination thereof.
Arun BALAKUMARAN, Cesar Adolfo SOMMER, Trevor Michael BENTLEY, Todd Webster SHEARER, Lesley Mary SMITH
Filed: 15 Jan 21
Utility
Selective Targeting of Host CD70+ Alloreactive Cells to Prolong Allogeneic Car T Cell Persistence
29 Dec 22
Provided herein are CD70-binding proteins comprising a CD70-binding domain and a transmembrane domain, engineered immune cells comprising the CD70-binding proteins, and methods of making and using the same.
Elvin J. LAURON, Siler PANOWSKI, Barbra Johnson SASU, Cesar Adolfo SOMMER, Surabhi SRIVATSA SRINIVASAN, Thomas John VAN BLARCOM, Shanshan LANG
Filed: 15 Jun 22
Utility
Fasl Expression and Fasr Gene Knockout to Protect Therapeutic Cells from Allogeneic Rejection and Activation-induced Cell Death
8 Sep 22
Compositions, methods, expression vectors and engineered immune cells for improving therapies that entail the administration of allogeneic cells to a patient.
Michael Thomas BETHUNE, Eric Hans GSCHWENG, Thomas John VAN BLARCOM, Cesar Adolfo SOMMER
Filed: 4 Mar 22
Utility
Methods for Transducing Immune Cells
11 Aug 22
Provided herein are improved methods for transducing immune cells, such as T cells, with retroviral vectors to express exogenous gene products, such as chimeric antigen receptors (CARs).
Todd LUMAN, Josergio ZARAGOZA, Abraham GERMANSDERFER, Suma RAO, Yajin NI, Chupei ZHANG, Tom Tao HUANG
Filed: 28 Jan 22
Utility
KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS
11 Aug 22
Provided herein are engineered immune cells and populations thereof for administration to patients to treat cancer (e.g., solid tumors or liquid tumors) and other conditions.
Michael Thomas BETHUNE, Eric Hans GSCHWENG, Thomas John VAN BLARCOM, Cesar Adolfo SOMMER, Michael C YI
Filed: 28 Jan 22
Utility
Formulations and Processes for Car T Cell Drug Products
4 Aug 22
Provided herein are formulations and drug product processes that can improve cell viability and minimize waste of the manufactured formulated cells for a drug product.
Muneeswara Babu MEDI, Zhuojin XU, Jung S. LEE, Yajin NI, Mark W. LEONARD
Filed: 3 Feb 22
Utility
Modified CASPASE-9 Polypeptides and Methods of Use Thereof
28 Jul 22
Provided herein are modified caspase-9 polypeptides, and chimeric caspase-9 proteins containing the modified caspase-9 polypeptides.
Meritxell GALINDO CASAS, Thomas John VAN BLARCOM
Filed: 8 Apr 22
Utility
Protease-activating CD45-GATE Car
21 Jul 22
A reversibly gated effector polypeptide e.g. a chimeric antigen receptor (protease-activating CD45-gate CAR) comprising an extracellular CD45 recruiting domain, a protease-cleavable linker, and a polypeptide comprising an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain.
Shanshan LANG, Thomas John VAN BLARCOM, Michael Thomas BETHUNE, Siler PANOWSKI, Nguyen TAN, Yi ZHANG, Barbra Johnson SASU, Zhe LI
Filed: 21 Dec 21
Utility
Methods and Reagents for Characterizing Car T Cells for Therapies
16 Jun 22
Provided herein are methods, kits and reagents for analyzing attributes of engineered immune cells, such as CAR T cells.
Lillian SEU, Melanie L. GEE, Michael A. BOWEN
Filed: 14 Dec 21
Utility
Modified caspase-9 polypeptides and methods of use thereof
10 May 22
Provided herein are modified caspase-9 polypeptides, and chimeric caspase-9 proteins containing the modified caspase-9 polypeptides.
Meritxell Galindo Casas, Thomas John Van Blarcom
Filed: 31 Oct 18
Utility
Inhibitory Chimeric Antigen Receptors
3 Feb 22
ARVIND RAJPAL, Shobha Chowdary Potluri, Laurent Poirot, Alexandre Juillerat, Thomas Charles Pertel, Donna Marie Stone, Barbra Johnson Sasu
Filed: 26 Jul 21
Utility
Chimeric Antigen Receptors with Enhanced Signaling and Activities and Uses Thereof
27 Jan 22
Provided herein are recombinant antigen receptors, for example chimeric antigen receptors (CARs), that comprise modified cytoplasmic domains that provide improved signalling and thereby provide improved performance and safety.
Michael Thomas BETHUNE, Yi ZHANG, Thomas John VAN BLARCOM, Siler PANOWSKI, Barbra Johnson SASU
Filed: 21 Jul 21